Christopher Straka

Title(s)Resident Physician, Radiation Medicine and Applied Science
SchoolHealth Sciences
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Ying J, Wang CJ, Yan J, Liauw SL, Straka C, Pistenmaa D, Xie XJ, Lotan Y, Roehrborn C, Kim DN. Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy. Am J Clin Oncol. 2017 Dec; 40(6):612-620. PMID: 26165416.
      View in: PubMed
    2. Kim DN, Straka C, Cho LC, Lotan Y, Yan J, Kavanagh B, Raben D, Cooley S, Brindle J, Xie XJ, Pistenmaa D, Timmerman R. Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 trial. Pract Radiat Oncol. 2017 Jan - Feb; 7(1):e43-e49. PMID: 27637137.
      View in: PubMed
    3. Straka C, Ying J, Kong FM, Willey CD, Kaminski J, Kim DW. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome. Springerplus. 2016; 5:229. PMID: 27026923; PMCID: PMC4771672.
    4. Kim DW, Straka C, Cho LC, Timmerman RD. Stereotactic Body Radiation Therapy for Prostate Cancer: Review of Experience of a Multicenter Phase I/II Dose-Escalation Study. Front Oncol. 2014; 4:319. PMID: 25505731; PMCID: PMC4245005.
    5. Kim DW, Cho LC, Straka C, Christie A, Lotan Y, Pistenmaa D, Kavanagh BD, Nanda A, Kueplian P, Brindle J, Cooley S, Perkins A, Raben D, Xie XJ, Timmerman RD. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014 Jul 01; 89(3):509-17. PMID: 24929162.
      View in: PubMed
    6. Straka C, Kim DW, Timmerman RD, Pedrosa I, Jacobs C, Brugarolas J. Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months. J Clin Oncol. 2013 Aug 10; 31(23):e401-3. PMID: 23796996; PMCID: PMC4878052.
    7. Jacobs C, Kim DW, Straka C, Timmerman RD, Brugarolas J. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib. J Clin Oncol. 2013 Mar 01; 31(7):e114-7. PMID: 23319695.
      View in: PubMed